A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

English version České info

The emergence of drug resistance during antiviral treatment limits treatment options and poses challenges to pharmaceutical development. Meanwhile, the search for novel antiviral compounds with chemical genetic screens has led to the identification of antiviral agents with undefined drug mechanisms. Daclatasvir, an effective NS5A inhibitor, is one such example. In traditional methods to identify critical residues governing drug-protein interactions, wild type virus is passaged under drug treatment pressure, enabling the identification of resistant mutations evolved after multiple viral passages. However, this method only characterizes a fraction of the positively selected variants. Here we have simultaneously quantified the relative change in replication fitness as well as the relative sensitivity to Daclatasvir for all possible single amino acid mutations in the NS5A domain IA, thereby identifying the entire panel of positions that interact with the drug. Using mathematical models, we predicted which mutations pose the greatest risk of causing emergence of resistance under different scenarios of treatment compliance. The mutant fitness and drug-sensitivity profiles obtained can also inform the patient-specific use of Daclatasvir and may facilitate the development of second-generation drugs with a higher genetic barrier to resistance.

Vyšlo v časopise: A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity. PLoS Pathog 10(4): e32767. doi:10.1371/journal.ppat.1004064
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004064

Souhrn

Zdroje

1. Chan M (2011) Antimicrobial resistance: no action today, no cure tomorrow. Atlanta, GA 30333, USA: Center of Disease Control and Prevention.

2. WuNC, YoungAP, DandekarS, WijersuriyaH, Al-MawsawiLQ, et al. (2013) Systematic Identification of H274Y Compensatory Mutations in Influenza A Virus Neuraminidase by High-Throughput Screening. Journal of Virology 87: 1193–1199.

3. Maisnier-PatinS, AnderssonDI (2004) Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 155: 360–369.

4. GhanyMG, StraderDB, ThomasDL, SeeffLB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335–1374.

5. FeldJJ, HoofnagleJH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967–972.

6. JacobsonIM, McHutchisonJG, DusheikoG, Di BisceglieAM, ReddyKR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.

7. PoordadF, McConeJJr, BaconBR, BrunoS, MannsMP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.

8. RobinsonM, TianY, DelaneyWEt, GreensteinAE (2011) Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc Natl Acad Sci U S A 108: 10290–10295.

9. ThompsonAJ, LocarniniSA, BeardMR (2011) Resistance to anti-HCV protease inhibitors. Curr Opin Virol 1: 599–606.

10. LohmannV, KörnerF, KochJ-O, HerianU, TheilmannL, et al. (1999) Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 285: 110–113.

11. BlightKJ, KolykhalovAA, RiceCM (2000) Efficient Initiation of HCV RNA Replication in Cell Culture. Science 290: 1972–1974.

12. WakitaT, PietschmannT, KatoT, DateT, MiyamotoM, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.

13. LindenbachBD, EvansMJ, SyderAJ, WolkB, TellinghuisenTL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623–626.

14. ZhongJ, GastaminzaP, ChengG, KapadiaS, KatoT, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294–9299.

15. De ClercqE (2012) The race for interferon-free HCV therapies: a snapshot by the spring of 2012. Rev Med Virol

16. ScheelTK, RiceCM (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19: 837–849.

17. BeldaO, Targett-AdamsP (2012) Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Research 170: 1–14.

18. AghemoA, De FrancescoR (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58: 428–438.

19. LemmJA, O'BoyleD, LiuM, NowerPT, ColonnoR, et al. (2010) Identification of Hepatitis C Virus NS5A Inhibitors. Journal of Virology 84: 482–491.

20. GaoM, NettlesRE, BelemaM, SnyderLB, NguyenVN, et al. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96–100.

21. TellinghuisenTL, EvansMJ, von HahnT, YouS, RiceCM (2007) Studying Hepatitis C Virus: Making the Best of a Bad Virus. Journal of Virology 81: 8853–8867.

22. GuedjJ, DahariH, RongL, SansoneND, NettlesRE, et al. (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences 110: 3991–3996.

23. LeeC, MaH, HangJQ, LevequeV, SklanEH, et al. (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414: 10–18.

24. FridellRA, QiuD, WangC, ValeraL, GaoM (2010) Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System. Antimicrobial Agents and Chemotherapy 54: 3641–3650.

25. WangC, HuangH, ValeraL, SunJ-H, O'BoyleDR, et al. (2012) Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052. Antimicrobial Agents and Chemotherapy 56: 1350–1358.

26. WangC, JiaL, HuangH, QiuD, ValeraL, et al. (2012) In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 56: 1588–1590.

27. FowlerDM, ArayaCL, FleishmanSJ, KelloggEH, StephanyJJ, et al. (2010) High-resolution mapping of protein sequence-function relationships. Nat Meth 7: 741–746.

28. MoyaA, ElenaSF, BrachoA, MirallesR, BarrioE (2000) The evolution of RNA viruses: A population genetics view. Proc Natl Acad Sci U S A 97: 6967–6973.

29. JonesCT, MurrayCL, EastmanDK, TasselloJ, RiceCM (2007) Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus. Journal of Virology 81: 8374–8383.

30. PeninFβ, BrassV, AppelN, RamboarinaS, MontserretR, et al. (2004) Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5A. Journal of Biological Chemistry 279: 40835–40843.

31. ElazarM, CheongKH, LiuP, GreenbergHB, RiceCM, et al. (2003) Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication. Journal of Virology 77: 6055–6061.

32. SongJ, Nagano-FujiiM, WangF, FloreseR, FujitaT, et al. (2000) Nuclear localization and intramolecular cleavage of N-terminally deleted NS5A protein of hepatitis C virus. Virus Research 69: 109–117.

33. ChoN-J, CheongKH, LeeC, FrankCW, GlennJS (2007) Binding Dynamics of Hepatitis C Virus' NS5A Amphipathic Peptide to Cell and Model Membranes. Journal of Virology 81: 6682–6689.

34. BrassV, BieckE, MontserretR, WolkB, HellingsJA, et al. (2002) An Amino-terminal Amphipathic α-Helix Mediates Membrane Association of the Hepatitis C Virus Nonstructural Protein 5A. Journal of Biological Chemistry 277: 8130–8139.

35. KayBK, WilliamsonMP, SudolM (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14: 231–241.

36. AdzhubeiAA, SternbergMJ, MakarovAA (2013) Polyproline-II Helix in Proteins: Structure and Function. J Mol Biol 425: 2100–2132.

37. TellinghuisenTL, MarcotrigianoJ, RiceCM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435: 374–379.

38. HuangL, HwangJ, SharmaSD, HargittaiMRS, ChenY, et al. (2005) Hepatitis C Virus Nonstructural Protein 5A (NS5A) Is an RNA-binding Protein. Journal of Biological Chemistry 280: 36417–36428.

39. FosterTL, BelyaevaT, StonehouseNJ, PearsonAR, HarrisM (2010) All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol 84: 9267–9277.

40. HwangJ, HuangL, CordekDG, VaughanR, ReynoldsSL, et al. (2010) Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 84: 12480–12491.

41. ScheelTKH, GottweinJM, MikkelsenLS, JensenTB, BukhJ (2011) Recombinant HCV Variants With NS5A From Genotypes 1‚7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α. Gastroenterology 140: 1032–1042.e1036.

42. FridellRA, WangC, SunJ-H, O'BoyleDR, NowerP, et al. (2011) Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations. Hepatology 54: 1924–1935.

43. NeumannAU, LamNP, DahariH, GretchDR, WileyTE, et al. (1998) Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy. Science 282: 103–107.

44. RongL, DahariH, RibeiroRM, PerelsonAS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.

45. KeR, LoverdoC, QiH, OlsonCA, WuNC, et al. (2013) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. Journal of Antimicrobial Chemotherapy 69: 724–727.

46. SulkowskiMS, GardinerDF, Rodriguez-TorresM, ReddyKR, HassaneinT, et al. (2013) 1417 Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (Rbv) In Chronic Hcv Genotype (Gt) 1-Infected Patients Who Previously Failed Telaprevir (Tvr) Or Boceprevir (Boc). Journal of Hepatology 58, Supplement 1: S570.

47. MannsMP, von HahnT (2013) Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12: 595–610.

48. LoveRA, BrodskyO, HickeyMJ, WellsPA, CroninCnN (2009) Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus. Journal of Virology 83: 4395–4403.

49. Moradpour D, Penin F (2013) Hepatitis C Virus Proteins: From Structure to Function. In: Bartenschlager R, editor. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Springer Berlin Heidelberg. pp. 113–142.

50. BergerKL, CooperJD, HeatonNS, YoonR, OaklandTE, et al. (2009) Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A 106: 7577–7582.

51. BergerKL, KellySM, JordanTX, TartellMA, RandallG (2011) Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J Virol 85: 8870–8883.

52. LimYS, HwangSB (2011) Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem 286: 11290–11298.

53. ReissS, RebhanI, BackesP, Romero-BreyI, ErfleH, et al. (2011) Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9: 32–45.

54. TaiAW, SalloumS (2011) The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 6: e26300.

55. ReissS, HarakC, Romero-BreyI, RadujkovicD, KleinR, et al. (2013) The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A. PLoS Pathog 9: e1003359.

56. NettlesRE, GaoM, BifanoM, ChungE, PerssonA, et al. (2011) Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54: 1956–1965.

57. WangC, SunJH, O'BoyleDR2nd, NowerP, ValeraL, et al. (2013) Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 57: 2054–2065.

58. PolS, GhalibRH, RustgiVK, MartorellC, EversonGT, et al. (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12: 671–677.

59. LokAS, GardinerDF, LawitzE, MartorellC, EversonGT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216–224.

60. RibeiroRM, LiH, WangS, StoddardMB, LearnGH, et al. (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8: e1002881.

61. RongL, GuedjJ, DahariH, CoffieldDJJr, LeviM, et al. (2013) Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 9: e1002959.